March 6, 2009 - ZOLL Commited to Advancing Alsius Temperature Management Technology For further information contact: ZOLL Medical CorporationAndrew Fleischacker+1 (978) 421-9693 Diane EganMedia Relations+1 (978) firstname.lastname@example.org ZOLL MEDICAL CORPORATION COMMITTED TO ADVANCING TEMPERATURE MANAGEMENT TECHNOLOGY March 6, 2009—CHELMSFORD, Mass.—ZOLL Medical Corporation (Nasdaq GS: ZOLL) announced today that its agreement with Alsius Corporation (Nasdaq: ALUS) to purchase the assets of Alsius’s intravascular temperature management device business demonstrates ZOLL’s commitment to become a leader in accurate, easy-to-use and cost effective control of body temperature in critical care patients. “Following the closing of our purchase, the entire complement of Alsius products will continue to be offered by ZOLL to meet the ongoing needs of Alsius customers and their patients,” stated Richard A. Packer, Chairman and CEO of ZOLL. “This includes both the Thermogard XP™ Advanced Temperature Management System as well as the CoolGard 3000® System. ZOLL intends to maintain the full line of Alsius catheters, all of which provide central venous infusion capabilities.” He added, “It is our goal to make this transition seamless.” As part of the transaction, ZOLL will provide all warranty and service obligations relating to the Alsius’ installed base of products. ZOLL plans to consolidate the operations of the acquired business at its facilities in Sunnyvale, California. The closing of the transaction is subject to the approval of Alsius shareholders and to other customary closing conditions. Mr. Packer added, “Alsius customers can feel confident knowing that ZOLL is a very well-capitalized company with significant cash reserves and no debt. We are committed to evolving the temperature management market and become the leading company in this space.” As the clinical community continues to expand the applications for therapeutic temperature management, ZOLL intends to work with the pioneers in temperature management to help expand the indications for therapeutic hypothermia. According to Mr. Packer, the speed and accuracy of cooling and the accuracy of subsequent re-warming that can be achieved with our endovascular technology will be unsurpassed. Mr. Packer concluded, “As we look to the future of therapeutic temperature management, we will be integrating the superior technologies from both Alsius and Radiant Medical, Inc., an earlier acquisition, in combination with ZOLL’s own developments in this area, to provide the very best solution for patients’ needs.” About ZOLL Medical Corporation ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information. ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the company’s resuscitation product development. For more information, visit www.zoll.com. Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on February 6, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements. Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, LifeBand, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.